Keya Medical
AI for Smarter Healthcare
contact
DEEPVESSEL FFR, Keya Medical Deep-Learning Based, Non-Invasive Coronary Artery Functional Assessment Software Device, Receives FDA Clearance.
Seattle, WA– April 1, 2022– Keya Medical announced that DEEPVESSEL FFR (DVFFR), has been cleared by U.S. Food and Drug Administration (FDA).
Diagnostic Solutions
Treatment Solutions
Solution Suites
Cardiology
Neurology
Pulmonology
Pathology
General Surgery
Cardio Suite
Stroke Suite
Diagnostic Solutions
Cardiology
Neurology
Pulmonology
Pathology
Treatment Solutions
Vascular Surgery
General Surgery
Solutions Suites
Cardio Suite
Stroke Suite
DeepVessel® FFR
Enabling better diagnosis and treatment of patients with coronary artery disease.
DeepVessel FFR uses deep learning technology to perform a non-invasive physiological functional assessment of the coronary arteries using coronary CT angiogram scans. The software reduces unnecessary invasive testing to lower costs and complications.
DeepVessel FFR is FDA cleared, CE Marked, National Medical Products Administration (NMPA) Approved.
Comprehensive R&D Pipeline Solution Suites
Keya Medical is developing a comprehensive R&D pipeline to deliver clinical value throughout the patient care process. The product candidates in our pipeline will be designed for use in early screening, diagnosis, treatment, and post-treatment maintenance.
Keya Medical: world’s leading AI medical device company
Keya Medical is dedicated to the development and commercialization of deep learning-based medical devices for disease diagnosis and treatment with a goal to revolutionize the medical device industry.
Keya Medical has developed solutions for specialties including cardiology, radiology, neurology, pathology, and surgery. Since 2016, we have collaborated with 728 hospitals to improve care delivery on a global scale.
Latest News
Subscribe to our monthly newsletter to receive exclusive news updates and medical AI insights.
DEEPVESSEL FFR, Keya Medical Deep-Learning Based, Non-Invasive Coronary Artery Functional Assessment Software Device, Receives FDA Clearance.
Seattle, WA– April 1, 2022– Keya Medical announced that DEEPVESSEL FFR (DVFFR), has been cleared by U.S. Food and Drug Administration (FDA).
Keya Medical Scientists Advance Image Segmentation Methods
Keya Medical’s computer scientists, working with colleagues at the Shenzhen Second People’s Hospital, have devised a new method that significantly boosts segmentation accuracy and performance.
Keya Medical received the Best Clinical Aided Decision-Making Product Award at GAIR2021.
GAIR2021 released the annual Best AI Digital Intelligence List. In the medical field, Keya Medical received the Best Clinical Aided Decision-Making Product Award for its flagship product DeepVessel FFR.
Let’s transform the future of healthcare together
Products
DeepVessel FFR
CuraRad-ICH
Solutions
All Solutions
Diagnostic Solutions
Treatment Solutions
Solution Suites
